Business Wire

CGTN

Share
CGTN: Tibetan Religious Leader Extends Wishes for Spring Festival, Tibetan New Year

The Tibetan New Year falls on the same day as the Spring Festival this year. As a long, bitter winter starts petering down, colorful spring sneaks in.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210212005297/en/

Bainqen Erdini Qoigyijabu, the 11th Panchen Lama, on Friday expressed best wishes to all Tibetans at home and abroad for both the Spring Festival and the Tibetan Year of the Iron Ox through China Media Group (CMG) and China Tibet Online.

Looking back at the past year, he expressed his affirmation that China has overcome difficulties in the face of the pandemic. "The whole country united together, and all people worked with one heart, achieving outstanding results in preventing and controlling the COVID-19 pandemic, which draws much worldwide attention," he said.

"From the pandemic, we have further understood how precious life is. As I see it, health, peace and happiness are the most precious fortune in human life. From the pandemic, we have also further understood that all human beings are in a community with a shared future."

He also expressed his understanding of the importance of a community with a shared future for mankind.

Erdini Qoigyijabu spoke of the historic alleviation of poverty in Tibet and of people in the region living and working in peace and contentment, and expressed his sincere gratitude to the country. "I feel very gratified to see the new Tibet today," he said. "A glorious time and a happy homeland is not a gift from nature. We should remain grateful for our country, and for the thousands upon thousands of people willing to sacrifice for us.”

Finally, he offered New Year blessings to the people of the whole country. "Let us jointly wish and pray the world be peaceful, the country be prosperous, the people live in peace, the weather be favorable, and all living things live joyfully! I wish everyone and every family be happy, safe and sound in the New Year and reap a new harvest," he concluded.

The Tibetan New Year, known as Losar, is the most important festival on the Tibetan calendar.

Celebrating Losar, Tibetan New Year, on the plateau

Losar is roughly the same as the Spring Festival of the Han ethnic group.

The Tibetan New Year is calculated based on the Tibetan calendar. It starts on the first day of the first month of the Tibetan calendar and ends on the 15th day. It falls on February 12 this year.

Originally a harvest celebration, the festival gradually shifted to the beginning of a new year, after Princess Wencheng of the Tang Dynasty (618-907) married Songtsen Gampo, the then Tibetan King, and brought to the southwestern Chinese region the culture of the Han people.

For the Tibetans and those who have been exploring the Tibetan New Year on the plateau, Tashi delek, and Happy New Year!

A developing Tibet

Transportation has long been a bottleneck inhibiting Tibet's development, as the region is situated on the Qinghai-Tibet Plateau with complex geographical conditions for road construction and limited technology and funds.

Since late 2012, China has been bolstering its infrastructure investment in Tibet. So far, roads have connected 95 percent of the township-level administrations and 75 percent of the incorporated villages in the region. The road network in Tibet now stretches over 117,000 kilometers, up by 50 percent from the end of 2015.

As for air transportation, Tibet has launched a total of 130 air routes, with 61 cities connected by flights; 5.18 million passenger trips were registered in 2020.

The development of Tibet is well-founded with data.

With the strong support of the central government and the active assistance from the local people, the economy of Tibet has been developing steadily.

In 2018, Tibet registered a GDP growth rate of 10 percent, the highest in China.

According to the released work reports from the local governments in February 2021, Tibet led the 2020 growth rate among the country's 31 provincial-level regions, at 7.8 percent, followed by southwestern provinces of Guizhou and Yunnan, at 4.5 and 4 percent, respectively.

In 2021, Tibet's GDP growth target stands at over 9 percent, while the pace is set around 8 percent for Guizhou and Yunnan provinces.

Original article: here .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye